PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
DNA vs. VIR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between DNA and VIR is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.4

Performance

DNA vs. VIR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ginkgo Bioworks Holdings, Inc. (DNA) and Vir Biotechnology, Inc. (VIR). The values are adjusted to include any dividend payments, if applicable.

-100.00%-95.00%-90.00%-85.00%-80.00%JulyAugustSeptemberOctoberNovemberDecember
-97.51%
-84.46%
DNA
VIR

Key characteristics

Sharpe Ratio

DNA:

-0.83

VIR:

-0.37

Sortino Ratio

DNA:

-1.82

VIR:

-0.18

Omega Ratio

DNA:

0.80

VIR:

0.98

Calmar Ratio

DNA:

-0.86

VIR:

-0.26

Martin Ratio

DNA:

-1.23

VIR:

-0.87

Ulcer Index

DNA:

69.09%

VIR:

27.19%

Daily Std Dev

DNA:

102.64%

VIR:

64.13%

Max Drawdown

DNA:

-99.10%

VIR:

-91.89%

Current Drawdown

DNA:

-98.31%

VIR:

-91.16%

Fundamentals

Market Cap

DNA:

$552.37M

VIR:

$1.01B

EPS

DNA:

-$12.89

VIR:

-$3.93

Total Revenue (TTM)

DNA:

$217.95M

VIR:

$78.62M

Gross Profit (TTM)

DNA:

$138.89M

VIR:

$64.40M

EBITDA (TTM)

DNA:

-$607.14M

VIR:

-$553.89M

Returns By Period

In the year-to-date period, DNA achieves a -85.09% return, which is significantly lower than VIR's -27.04% return.


DNA

YTD

-85.09%

1M

58.49%

6M

-40.62%

1Y

-85.68%

5Y*

N/A

10Y*

N/A

VIR

YTD

-27.04%

1M

5.61%

6M

-19.69%

1Y

-27.40%

5Y*

-10.17%

10Y*

N/A

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

DNA vs. VIR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and Vir Biotechnology, Inc. (VIR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for DNA, currently valued at -0.83, compared to the broader market-4.00-2.000.002.00-0.83-0.37
The chart of Sortino ratio for DNA, currently valued at -1.82, compared to the broader market-4.00-2.000.002.004.00-1.82-0.18
The chart of Omega ratio for DNA, currently valued at 0.80, compared to the broader market0.501.001.502.000.800.98
The chart of Calmar ratio for DNA, currently valued at -0.86, compared to the broader market0.002.004.006.00-0.86-0.27
The chart of Martin ratio for DNA, currently valued at -1.23, compared to the broader market-5.000.005.0010.0015.0020.0025.00-1.23-0.87
DNA
VIR

The current DNA Sharpe Ratio is -0.83, which is lower than the VIR Sharpe Ratio of -0.37. The chart below compares the historical Sharpe Ratios of DNA and VIR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.80-0.60-0.40-0.200.000.200.40JulyAugustSeptemberOctoberNovemberDecember
-0.83
-0.37
DNA
VIR

Dividends

DNA vs. VIR - Dividend Comparison

Neither DNA nor VIR has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

DNA vs. VIR - Drawdown Comparison

The maximum DNA drawdown since its inception was -99.10%, which is greater than VIR's maximum drawdown of -91.89%. Use the drawdown chart below to compare losses from any high point for DNA and VIR. For additional features, visit the drawdowns tool.


-100.00%-95.00%-90.00%-85.00%-80.00%JulyAugustSeptemberOctoberNovemberDecember
-98.31%
-86.54%
DNA
VIR

Volatility

DNA vs. VIR - Volatility Comparison

Ginkgo Bioworks Holdings, Inc. (DNA) has a higher volatility of 35.69% compared to Vir Biotechnology, Inc. (VIR) at 22.31%. This indicates that DNA's price experiences larger fluctuations and is considered to be riskier than VIR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%JulyAugustSeptemberOctoberNovemberDecember
35.69%
22.31%
DNA
VIR

Financials

DNA vs. VIR - Financials Comparison

This section allows you to compare key financial metrics between Ginkgo Bioworks Holdings, Inc. and Vir Biotechnology, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab